| DAY 1 - Friday, 18 October 2024 | ||
| 08.40 - 09.00 | Welcome and Introduction to EndoBridge 2024 | |
| 09.00 - 11.00 MAIN HALL |
||
| 09:00 - 09:30 | Management of Cushing disease | |
| 09:30 - 10:00 | Genetics of pituitary adenomas and their relevance in clinical care | |
| 10:00 - 10:30 | Approach to aggressive pituitary tumors | |
| 10:30 - 11:00 | TBC | |
| 11.00 - 11.20 | Coffee Break | |
| 11.20 - 12.50 | Interactive Case Discussion Sessions | |
| HALL A | Pituitary | |
| HALL B | Adrenal | |
| HALL C | Neuroendocrine Tumors | |
| HALL D | Male Reproductive Endocrinology | |
| 12.50 - 14.00 | Lunch | |
| 14.00 - 15.30 | Interactive Case Discussion Sessions | |
| HALL A | Pituitary | |
| HALL B | Adrenal | |
| HALL C | Neuroendocrine Tumors | |
| HALL D | Female Reproductive Endocrinology | |
| 15.30 - 15.50 | Coffee Break | |
| 15.50 - 17.50 MAIN HALL |
||
| 15:50 - 16:20 | Adrenal Insufficiency - common and rare causes – from biology to clinical care | |
| 16:20 - 16:50 | Updates on male hypogonadism and infertility | |
| 16:50 - 17:20 | TBC | |
| 17:20 - 17:50 | TBC | |
| DAY 2 - Saturday, 19 October 2024 | ||
| 09.00 - 11.00 MAIN HALL |
||
| 09:00 - 09:30 | Osteoporosis in children and adolescents | |
| 09:30 - 10:00 | Diabetes, obesity and bones | |
| 10:00 - 10:30 | Bone loss and fractures post denosumab discontinuation | |
| 10:30 - 11:00 | Goal directed therapy- BHOF- ASBMR position | |
| 11.00 - 11.20 | Coffee Break | |
| 11.20 - 12.50 | Interactive Case Discussion Sessions | |
| HALL A | Diabetes | |
| HALL B | Thyroid | |
| HALL C | Bone and Calcium | |
| HALL D | Obesity, Metabolism and Nutrition | |
| 12.50 - 14.00 | Lunch | |
| 14.00 - 15.30 | Interactive Case Discussion Sessions | |
| HALL A | Diabetes | |
| HALL B | Thyroid | |
| HALL C | Bone and Calcium | |
| HALL D | Obesity, Metabolism and Nutrition | |
| 15.30 - 15.50 | Coffee Break | |
| 15.50 - 17.50 MAIN HALL |
||
| 15:50 - 16:20 | Update on ATA pregnancy guidelines | |
| 16:20 - 16:50 | Update on ATA nodule guidelines | |
| 16:50 - 17:20 | Update on ATA cancer guidelines | |
| 17:20 - 17:50 | Treatment of subclinical thyroid disease | |
| DAY 3 - Sunday, 20 October 2024 | ||
| 09.00 - 11.00 MAIN HALL |
||
| 09:00 - 09:30 | Phenotyping obesities: Reality or utopia | |
| 09:30 - 10:00 | Evidence and experience-based obesity pharmacotherapy | |
| 10:00 - 10:30 | Obesity management in preventing and treating MASLD | |
| 10:30 - 11:00 | GLP-1R agonists & cardiovascular outcomes in obesity without diabetes | |
| 11.00 - 11.20 | Coffee Break | |
| 11.20 - 13.20 MAIN HALL |
||
| 11:20 - 11:50 | Diabetes in pregnancy | |
| 11:50 - 12:20 | Revolutionizing diabetes management with once weekly insulins | |
| 12:20 - 12:50 | Technology in T2DM | |
| 12:50 - 13:20 | Adjunct therapies for type 1 diabetes | |
| 13.20 - 13.30 | Closing comments and adjourn | |
